Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 2/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545485 | 0.86 | CRBN (0.37) | CRBNDRD2DRD4CA9TRPV1 | |
| SCHEMBL3596520 | 0.84 | CRBN (0.34) | CRBNDRD2DRD4CA9TRPV1 | |
| SCHEMBL13545483 | 0.84 | CRBN (0.34) | CRBNDRD2DRD4CA9TRPV1 | |
| SCHEMBL3605706 | 0.83 | PARP1 (0.32) | FKBP1ACRBNCA9DUTTOP2A | |
| SCHEMBL13545486 | 0.78 | CRBN (0.38) | CRBNDRD2DRD4CA9TRPV1 | |
| SCHEMBL3596516 | 0.76 | ALOX15 (0.33) | CRBNCA9 | |
| SCHEMBL3595503 | 0.76 | CA9 (0.39) | CRBNDRD2DRD4CA9TRPV1 | |
| SCHEMBL3596750 | 0.75 | CRBN (0.41) | CRBNDRD2DRD4CA9TRPV1 | |
| SCHEMBL13545482 | 0.75 | CRBN (0.41) | CRBNDRD2DRD4CA9TRPV1 | |
| SCHEMBL3602519 | 0.74 | CRBN (0.40) | CRBNDRD2DRD4CA9TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | FKBP1A 2792/4885CRBN 762/4885DRD2 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.